ATE453667T1 - Neovaskular-spezifische peptide - Google Patents

Neovaskular-spezifische peptide

Info

Publication number
ATE453667T1
ATE453667T1 AT99947941T AT99947941T ATE453667T1 AT E453667 T1 ATE453667 T1 AT E453667T1 AT 99947941 T AT99947941 T AT 99947941T AT 99947941 T AT99947941 T AT 99947941T AT E453667 T1 ATE453667 T1 AT E453667T1
Authority
AT
Austria
Prior art keywords
cancer
peptides
neovascular
specific peptides
tissues
Prior art date
Application number
AT99947941T
Other languages
English (en)
Inventor
Naoto Oku
Koichi Ogino
Dai Ishikawa
Michinori Tanaka
Takao Taki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE453667T1 publication Critical patent/ATE453667T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99947941T 1998-10-16 1999-10-15 Neovaskular-spezifische peptide ATE453667T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP29519898 1998-10-16
JP19470699 1999-07-08
PCT/JP1999/005730 WO2000023476A1 (en) 1998-10-16 1999-10-15 Neovascular-specific peptides

Publications (1)

Publication Number Publication Date
ATE453667T1 true ATE453667T1 (de) 2010-01-15

Family

ID=26508673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99947941T ATE453667T1 (de) 1998-10-16 1999-10-15 Neovaskular-spezifische peptide

Country Status (11)

Country Link
US (1) US6753310B1 (de)
EP (2) EP1783140A3 (de)
JP (1) JP4439120B2 (de)
AT (1) ATE453667T1 (de)
CA (2) CA2622786A1 (de)
CY (1) CY1109881T1 (de)
DE (1) DE69941877D1 (de)
DK (1) DK1122262T3 (de)
ES (1) ES2337321T3 (de)
PT (1) PT1122262E (de)
WO (1) WO2000023476A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527398A (ja) * 2000-03-16 2003-09-16 ユニヴァーシティ オブ ピッツバーグ 内皮特異性ターゲティング
US7186693B2 (en) * 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7071164B2 (en) * 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
RU2326691C2 (ru) * 2002-07-18 2008-06-20 Хеликс Биофарма Корп. Использование уреазы для ингибирования роста раковых клеток
US7148194B2 (en) * 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) * 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds
US8440217B1 (en) 2005-06-15 2013-05-14 Mawaheb M. EL-Naggar Method and system with contact lens product for treating and preventing adverse eye conditions
JP5250229B2 (ja) * 2007-09-25 2013-07-31 独立行政法人科学技術振興機構 カーボンナノホーン
WO2009048870A1 (en) * 2007-10-08 2009-04-16 Baylor College Of Medicine Peptide dendrimers: affinity reagents for binding noroviruses
JP2011512364A (ja) * 2008-02-22 2011-04-21 インター−ケイ ピーティーワイ リミテッド 治療用ペプチド
AU2010321739A1 (en) * 2009-11-23 2012-05-31 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622852A (en) * 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
JP4173544B2 (ja) * 1995-11-16 2008-10-29 ノバルティス アクチエンゲゼルシャフト 治療剤としての、または診断におけるｒａｃ−プロテインキナーゼ
US5922676A (en) * 1996-09-20 1999-07-13 The Burnham Institute Methods of inhibiting cancer by using superfibronectin
CH692507A5 (de) * 1997-04-26 2002-07-15 Peter Prof Dr Sonderegger Neurotrypsin als aktive Verbindung in einem Medikament.
WO1999029858A1 (en) * 1997-12-09 1999-06-17 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
JPH11243964A (ja) * 1998-03-03 1999-09-14 Natl Food Res Inst イネオルニチンカルバミルトランスフェラーゼ遺伝子、該遺伝子を含むベクター及び形質転換体
EP0950709A1 (de) * 1998-04-17 1999-10-20 Hoechst Marion Roussel Deutschland GmbH Antisense Oligonukleotide zur Hemmung der Expression der Integrin alphaV Untereinheit
AU758074B2 (en) 1998-04-29 2003-03-13 Genesis Research And Development Corporation Limited Polynucleotides isolated from skin cells and methods for their use
NZ507912A (en) 1998-05-22 2002-10-25 Abbott Lab Nonapeptide antiangiogenic drugs

Also Published As

Publication number Publication date
WO2000023476A1 (en) 2000-04-27
EP1122262B1 (de) 2009-12-30
JP4439120B2 (ja) 2010-03-24
PT1122262E (pt) 2010-01-27
ES2337321T3 (es) 2010-04-22
US6753310B1 (en) 2004-06-22
DK1122262T3 (da) 2010-04-19
EP1122262A4 (de) 2003-05-21
EP1783140A3 (de) 2007-07-11
EP1783140A2 (de) 2007-05-09
DE69941877D1 (de) 2010-02-11
CA2347136A1 (en) 2000-04-27
CA2622786A1 (en) 2000-04-27
EP1122262A1 (de) 2001-08-08
CY1109881T1 (el) 2014-09-10

Similar Documents

Publication Publication Date Title
CY1109881T1 (el) Νεοαγγειακα-συγκεκριμενα πεπτιδια
ATE382055T1 (de) Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren
EP0997152A4 (de) Arzneimittel gegen lymphatische tumore
PT765152E (pt) Estimulacao do crescimento capilar por complexos de peptido-cobre
DE69838143D1 (de) Antimikrobielle peptide
ATE412004T1 (de) Transfektions-komplexe
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
WO2001085777A3 (en) Therapeutic pore-forming peptides
ATE521702T1 (de) Krebsantigene und deren nutzung
WO2002058589A3 (en) Agents and methods for promoting bone growth
NO20011817D0 (no) Ionebytte-tumormålsöking (IETT)
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DK0938329T3 (da) Immunogen TLP sammensætning
FR2795415B1 (fr) Compose peptidique derive d'une orf decalee du gene ice
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
WO2002100897A3 (fr) Complexes moleculaires brca1/acc alpha, applications diagnostiques et therapeutiques
WO2001098363A3 (en) Peptides for use in the immunotherapy of renal cell carcinoma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1122262

Country of ref document: EP